FibroGen(FGEN) - 2025 Q4 - Annual Results

Exhibit 99.1 Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the fourth quarter and full year 2025 and provided an update on the company's recent developments. "The encouraging results from the investigator-sponsored combination trial of FG-3246 with enzalutamide provide us with valuable insights and reinforce key design elements in our Phase 2 ...